Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 8/20 | 0.53 |
| ▸ | LTA4H | P09960 | 1/20 | 0.52 |
| ▸ | DRD3 | P35462 | 4/20 | 0.50 |
| ▸ | DRD2 | P14416 | 2/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21780738 | 0.88 | KDM1A (0.54) | ESR1 | |
| SCHEMBL21780731 | 0.85 | HRH3 (0.49) | ESR1LTA4HDRD3DRD2 | |
| SCHEMBL17845178 | 0.84 | ESR1 (0.56) | ESR1 | |
| SCHEMBL20683542 | 0.84 | ESR1 (0.47) | ESR1 | |
| SCHEMBL17838456 | 0.84 | KDM4E (0.56) | ESR1LTA4H | |
| SCHEMBL17087008 | 0.84 | KDM1A (0.56) | ESR1LTA4H | |
| SCHEMBL23474910 | 0.84 | KDM4E (0.62) | ESR1LTA4H | |
| SCHEMBL23475063 | 0.84 | MEN1 (0.54) | ESR1LTA4H | |
| SCHEMBL17845103 | 0.81 | ESR1 (0.44) | ESR1 | |
| SCHEMBL16361996 | 0.81 | ESR1 (0.44) | ESR1LTA4H |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240226073-A9 | TETRAHYDRO-1H-PYRIDO[3,4-b]INDOLE ANTI-ESTROGENIC DRUGS | OLEMA PHARMACEUTICALS, INC. | 2024-07-11 | — | — | US | disclosed |
| US-11672785-B2 | Tetrahydro-1H-pyrido [3,4-b]indole anti-estrogenic drugs | OLEMA PHARMACEUTICALS, INC. (US) | 2023-06-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11672785-B2 | Tetrahydro-1H-pyrido [3,4-b]indole anti-estrogenic drugs | ESR1, CYP19A1, HSD17B11 | ESR1 1/4885LTA4H 1812/4885DRD3 825/4885 |
| US-20240226073-A9 | TETRAHYDRO-1H-PYRIDO[3,4-b]INDOLE ANTI-ESTROGENIC DRUGS | ESR1, CYP19A1, HSD17B11 | ESR1 1/4885LTA4H 1812/4885DRD3 825/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.